# Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)

> **NCT01717664** · PHASE2 · COMPLETED · sponsor: **RedHill Biopharma Limited** · enrollment: 18 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** RHB-104

## Key facts

- **NCT ID:** NCT01717664
- **Lead sponsor:** RedHill Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-12
- **Final completion:** 2016-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01717664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01717664, "Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01717664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*